Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X1LO
|
||||
| Former ID |
DIB016292
|
||||
| Drug Name |
EMR-62203
|
||||
| Synonyms |
EMR-6203; PDE 5 inhibitor, Merck KGaA
|
||||
| Indication | Erectile dysfunction [ICD9: 302.72, 607.84; ICD10:F52.2, N48.4] | Discontinued in Phase 2 | [1] | ||
| Company |
Merck KGaA
|
||||
| Target and Pathway | |||||
| Target(s) | CGMP-specific 3',5'-cyclic phosphodiesterase | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Purine metabolism | ||||
| cGMP-PKG signaling pathway | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | cGMP effects | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018868) | ||||
| REF 2 | WO patent application no. 2006,0180,88, Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.